Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Sarcoma 2

Conditions

Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 8Recurrence 7Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Lymphoma 4Dendritic Cell Sarcoma, Interdigitating 2Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Cytokine Release Syndrome 1Aggression 1

Interventions

glofitamab 2Rituximab 2Cyclophosphamide 2zanubrutinib 1pirtobrutinib 1pegfilgrastim 1obinutuzumab 1mirabegron 1Vincristine 1Specimen Handling 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Lenalidomide 1Doxorubicin 1Dexrazoxane 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Dendritic Cell Sarcoma, Interdigitating × glofitamab × Clear all
NCT04889716 2026-05-26

CAR-T Followed by Bispecific Antibodies

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
23 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT06481826 2026-03-27

Glofitamab in Chinese Patients With R/R DLBCL

Peking Union Medical College Hospital

Recruiting
20 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡